


**Product Name** : CEP-37440  
**Cat. No.** : PC-20623  
**CAS No.** : 1391712-60-9  
**Molecular Formula** : C<sub>30</sub>H<sub>38</sub>ClN<sub>7</sub>O<sub>3</sub>  
**Molecular Weight** : 580.13  
**Target** : Anaplastic Lymphoma Kinase (ALK)  
**Solubility** : 10 mM in DMSO



## Biological Activity

CEP-37440 (ESK440, CEP37440) is a potent, selective, and brain penetrant dual **FAK/ALK** inhibitor with IC<sub>50</sub> of 2.0/3.1 nM, respectively.

CEP-37440 exhibits a K<sub>d</sub> value of 3.6 nM for ALK (WT), displays similar potencies for the ALK mutants ALK (L1151Tins, K<sub>d</sub> 2.6 nM), ALK (C1156Y, K<sub>d</sub>=1.6 nM), ALK (F1174L, K<sub>d</sub>=1.1 nM, as well as the gatekeeper mutation ALK (L1196M, K<sub>d</sub>=3.3 nM).

CEP-37440 exhibits selectivity against the full DiscoverX kinase panel (442 kinases) at 1 μM.

CEP-37440 at low concentration decreases the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4, while not affecting the proliferation of normal breast epithelial cells.

CEP-37440 decreases the cell proliferation of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397).

CEP-37440 affects the expression of genes related to apoptosis, affects the expression of genes related to apoptosis, interferon signaling, and cytokines, exhibits SUM190, FC-IBC02, and SUM149 breast tumor xenografts.

## References

Ott GR, et al. *J Med Chem*. 2016 Aug 25;59(16):7478-96.

Salem I, et al. *Breast Cancer Res*. 2016 Mar 24;18(1):37.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com